Leukemia

In a phase 1/2 trial, patients with refractory or relapsed AML with FLT3 mutation (n=191; ITD n=162, D835 n=13, ITD-D835 n=16) received gilteritinib. 49% (93/191) of patients achieved an overall respo… (full text at CIViC)

PMID 28645776 · Perl et al., 2017 · Open in CIViC

Midostaurin is FDA-approved for the treatment of newly-diagnosed acute myeloid leukemia patients harboring FLT3 mutations.

PMID 28546144 · Levis, 2017 · Open in CIViC

Of the 14 AML patients receiving nilotinib, 80% achieved complete remission or complete remission with incomplete platelet recovery. Genetic testing revealed that 27% of these individuals conferred a … (full text at CIViC)

PMID 28720666 · Shen et al., 2017 · Open in CIViC

Compared to non-treated control cells, MV4-11 cells (FLT3 mutated cell line) that were exposed to nilotinib (30 uM) showed a 58% reduction in colony numbers.Further evidence to support cell death incl… (full text at CIViC)

PMID 28720666 · Shen et al., 2017 · Open in CIViC

The ability of FLT3-N676K mutation to induce leukemia by itself in mouse models is explored in this study. Furthermore, the leukemogenic potential of FLT3-N676K is compared to two well established, ca… (full text at CIViC)

PMID 26891877 · Huang et al., 2016 · Open in CIViC

In a cohort of 84 de novo AML patients with a CBFB/MYH11 rearrangement and in 36 patients with a RUNX1/RUNX1T1 rearrangement, the FLT3 N676K mutation was identified in 5 and 1 patients, respectively (… (full text at CIViC)

PMID 23878140 · Opatz et al., 2013 · Open in CIViC

This study identified genetic driver mutations by sequencing 111 genes and cytogenetic studies in 1540 samples across three different clinical trials. Table S5 shows all mutations identified in the sa… (full text at CIViC)

PMID 27276561 · Papaemmanuil et al., 2016 · Open in CIViC

In 65 hematologic cancer patient samples (53 AML, 9 ALL, and 3 MDS) partially enriched for lacking FLT3 ITD mutations, resequencing of 21/24 FLT3 exons was performed. In 2 patients with AML, the novel… (full text at CIViC)

PMID 15178581 · Jiang et al., 2004 · Open in CIViC

This study identified genetic driver mutations by sequencing 111 genes and cytogenetic studies in 1540 samples across three different clinical trials. The prognostic significance of FLT3 tyrosine kina… (full text at CIViC)

PMID 27276561 · Papaemmanuil et al., 2016 · Open in CIViC

The study screened for mutations in the second tyrosine kinase domain of FLT3 (TK2) in 172 untreated patient with de novo AML. Nonisotopic RNase cleavage assay was used to identify samples that did no… (full text at CIViC)

PMID 15625552 · Matsuno et al., 2005 · Open in CIViC

This study identified genetic driver mutations by sequencing 111 genes and cytogenetic studies in 1540 samples across three different clinical trials. The prognostic significance of FLT3 tyrosine kina… (full text at CIViC)

PMID 27276561 · Papaemmanuil et al., 2016 · Open in CIViC

A 25-year-old Caucasian male presented with a second relapse of B-ALL. RNA sequencing revealed FLT3 overexpression (also confirmed by IHC). The patient was treated with 22 days of sunitinib, permittin… (full text at CIViC)

PMID 27181063 · Griffith et al., 2016 · Open in CIViC

In some cancers such as infant ALL, B-lineage ALL and AML samples with the highest levels of wild-type FLT3, constitutive FLT3 phosphorylation is seen from paracrine or autocrine activation from FLT3 … (full text at CIViC)

PMID 28077790 · Nguyen et al., 2017 · Open in CIViC

46-year-old woman with normal karyotype AML; negative for ITD mutation by PCR-based FLT3 testing. Based on negative FLT3-ITD: Treated with phase 1B standard cytarabine and daunorubicin (7+3) induction… (full text at CIViC)

PMID 33914060 · Young et al., 2021 · Open in CIViC

46-year-old woman with normal karyotype AML; negative for ITD mutation by PCR-based FLT3 testing. Based on negative FLT3-ITD: Treated with phase 1B standard cytarabine and daunorubicin (7+3) induction… (full text at CIViC)

PMID 33914060 · Young et al., 2021 · Open in CIViC

The construct supported IL-3 independent growth of Ba/F3 cells. It showed FLT-3 autophosphorylation and downstream signaling via STAT5, AKT, and ERK1/2 pathways. With IL-3 deprivation, the cells showe… (full text at CIViC)

PMID 33914060 · Young et al., 2021 · Open in CIViC

In AML patients, FLT3-TKD mutation was associated with poorer disease free survival compared to patients with wild type FLT3.

PMID 17940205 · Whitman et al., 2008 · Open in CIViC

Event-free survival was significantly improved in patients with both NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone 2) either NPM1 or FLT3-TKD when FLT3-ITD patients… (full text at CIViC)

PMID 17965322 · Bacher et al., 2008 · Open in CIViC

In an in vitro study, MOLM-14, PL21 and MV4-11 cell lines expressing FLT3 internal tandem duplication mutation (FLT3-ITD) demonstrated increased sensitivity to palbociclib treatment, compared to THP-1… (full text at CIViC)

PMID 27099147 · Uras et al., 2016 · Open in CIViC

In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 internal tandem duplication mutation (n=2) were associated with improved response to sunitinib treatment. The pat… (full text at CIViC)

PMID 15459012 · Fiedler et al., 2005 · Open in CIViC

The FLT3 V592G variant was found in a patient with AML. BaF3 cells transformed to express V592G demonstrated proliferation in the absence of IL-3 similar to D835Y positive control. Cell proliferation … (full text at CIViC)

PMID 18068628 · Fröhling et al., 2007 · Open in CIViC

Longitudinal study analyzing blood samples over time for CHIP. The V592I was found with a VAF 0.53% (below normal CHIP threshold) in a control individual who did not develop AML.

PMID 31004019 · Young et al., 2019 · Open in CIViC

Found in whole blood of patient (ID# 4973, appendix 2) with AML, mutational profile included FLT3 V592I VAF 55%; FLT3-ITD VAF 25%, NPM1 c.863_864insCCTG VAF 25%, DNMT3A p.Arg882His VAF 43%

PMID 37586297 · Hogg et al., 2023 · Open in CIViC

Ba/F3 cell lines engineered to express Y572C showed sustained growth in the absence of IL-3 similar to the FLT3-ITD cell line (Figure 2A). The Ba/F3 WT expressing cell line showed growth with additio… (full text at CIViC)

PMID 39806020 · Anabtawi et al., 2025 · Open in CIViC

The paper includes 1660 newly diagnosed de novo AML cases on frontline CALGB and a total of 37 point mutations and deletions were identified in the juxtamembrane domain of the FLT3 gene. Three patient… (full text at CIViC)

PMID 39806020 · Anabtawi et al., 2025 · Open in CIViC